2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2822

Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Abstract Number: 2823

Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Abstract Number: 2824

On Tapering Therapy for RA Patients in Clinical Remission; Flare on Csdmards Predicted By Clinical Features and Musculoskeletal Ultrasound, Whereas T-Cell Abnormalities Predictive for b-DMARD Tapering
Abstract Number: 2825

Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Abstract Number: 2826

Emergence of Severe Spondyloarthropathy Related Entheseal Pathology Following Successful Vedolizumab Therapy for Inflammatory Bowel Disease
Abstract Number: 2827

Remission Targets and Prevention of Subclinical Atherosclerosis in Psoriatic Arthritis- Which Target Should We Choose?
Abstract Number: 2828

Utility of Fecal Calprotectin Levels for the Diagnosis of Inflammatory Bowel Disease in Patients with Spondylorarthritis
Abstract Number: 2829

The Response to TNF-Blockers Treatment of Spa Patients Is Influenced By the Interplay between HLA-B27 and Gut Microbiota Composition at Baseline
Abstract Number: 2830

Synovitis in Psoriatic Arthritis and Seronegative Rheumatoid Arthritis: Differential Histological Features
Abstract Number: 2831

High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Abstract Number: 2832

Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2
Abstract Number: 2833

Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Abstract Number: 2834

The Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients with Systemic Lupus Erythematosus
Abstract Number: 2835

Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus
Abstract Number: 2836

Measurement of Interferon Alpha Expression Using Multiple Methodologies Identifies a Signature in a Subgroup of Connective Tissue Disease Patients with Haematological Abnormalities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].